Blair William & Co. IL Purchases 1,297 Shares of Stryker Co. (NYSE:SYK)

Blair William & Co. IL raised its holdings in Stryker Co. (NYSE:SYK - Free Report) by 0.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 931,674 shares of the medical technology company's stock after acquiring an additional 1,297 shares during the quarter. Stryker accounts for about 1.0% of Blair William & Co. IL's portfolio, making the stock its 18th biggest holding. Blair William & Co. IL owned 0.24% of Stryker worth $335,449,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in SYK. Swedbank AB lifted its holdings in shares of Stryker by 10.9% during the third quarter. Swedbank AB now owns 51,070 shares of the medical technology company's stock valued at $18,450,000 after purchasing an additional 5,032 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Stryker during the 3rd quarter worth about $317,000. Avestar Capital LLC boosted its holdings in shares of Stryker by 1.1% in the third quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company's stock worth $1,065,000 after buying an additional 31 shares during the period. Townsquare Capital LLC increased its position in shares of Stryker by 11.9% in the third quarter. Townsquare Capital LLC now owns 7,468 shares of the medical technology company's stock worth $2,698,000 after acquiring an additional 792 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Stryker by 162.3% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 144,283 shares of the medical technology company's stock worth $52,124,000 after acquiring an additional 89,283 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Remove Ads

Stryker Stock Performance

Shares of SYK stock traded down $3.16 during trading on Friday, reaching $364.38. The company had a trading volume of 1,274,307 shares, compared to its average volume of 1,289,456. The company has a market capitalization of $139.08 billion, a PE ratio of 46.96, a PEG ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm's 50 day simple moving average is $384.08 and its two-hundred day simple moving average is $374.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the company earned $3.46 EPS. Sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.92%. Stryker's dividend payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on SYK shares. Stifel Nicolaus upped their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Argus set a $450.00 target price on Stryker in a report on Monday, February 3rd. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Finally, Citigroup reaffirmed a "buy" rating and set a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $421.90.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.